Differential Amplification and Overexpression of HER-2/neu, p53, MIB1, and Estrogen Receptor/Progesterone Receptor among Medullary Carcinoma, Atypical Medullary Carcinoma, and High-Grade Invasive Ductal Carcinoma of Breast

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 11, 2003, Pages 1458-1464

  Xu, Ruliang ^a   Feiner, Helen ^b,c   Li, Peng ^c   Yee, Herman ^c   Inghirami, Giorgio ^c   Delgado, Yara ^c   Perle, Mary Ann ^c,d  

^a NEW YORK UNIVERSITY   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ATYPICAL MEDULLARY CARCINOMA; BREAST CARCINOMA; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HIGH GRADE INVASIVE DUCTAL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDULLARY CARCINOMA; ONCOGENE NEU; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; COMPARATIVE STUDY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROTO ONCOGENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, MEDULLARY; DIAGNOSIS, DIFFERENTIAL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENES, P53; HUMANS; KI-67 ANTIGEN; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0242304207     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977;40:1365-1385.
2. Rapin V, Contesso G, Mouriesse H, et al. Medullary breast carcinoma: a reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer. 1988;61:2503-2510.
3. Wargotz ES, Silverberg SG. Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. Hum Pathol. 1988;19:1340-1346.
4. Jensen ML, Kiaer H, Andersen J, Jensen J, Melsen F. Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology. 1997;30:523-532.
5. Gaffey MJ, Mills SE, Frierson HF Jr, et al. Medullary carcinoma of the breast: interobserver variability in histopathologic diagnosis. Mod Pathol. 1995;8:31-38.
6. Rigaud C, Theobald S, Noel P, et al. Medullary carcinoma of the breast: a multicenter study of its diagnostic consistency. Arch Pathol Lab Med. 1993;117:1005-1008.
7. Rubens JR, Lewandroski KB, Kopans DB, Koerner FC, Hall DA, McCarthy KA. Medullary carcinoma of the breast: overdiagnosis of a prognostically favorable neoplasm. Arch Surg. 1990;125:601-604.
8. Liberman L, LaTrenta LR, Samli B, Morris EA, Abramson AF, Dershaw DD. Overdiagnosis of medullary carcinoma: a mammographic-pathologic correlative study. Radiology. 1996;201:443-446.
9. Cheung YC, Chen SC, Lee KF, Wan YL, Ng SH. Sonographic and pathologic findings in typical and atypical medullary carcinomas of the breast. J Clin Ultrasound. 2000;28:325-331.
10. Lloreta J, Marinoso ML, Corominas JM, Canas MA, Serrano S. Medullary carcinoma of the breast: an ultrastructural morphometric study of nine cases. Ultrastruct Pathol. 1997;21:499-507.
11. Harris M, Lessells AM. The ultrastructure of medullary, atypical medullary and non-medullary carcinomas of the breast. Histopathology. 1986;10:405-414.
12. Tot T. The cytokeratin profile of medullary carcinoma of the breast. Histopathology. 2000;37:175-181.
13. Toth T. Cytokeratins 7 and 14 in special types of invasive breast carcinomas. Med Pregl. 1999;52:227-232.
14. Jensen ML, Kiaer H, Melsen F. Medullary breast carcinoma vs. poorly differentiated ductal carcinoma: an immunohistochemical study with keratin 19 and oestrogen receptor staining. Histopathology. 1996;29:241-245.
15. Dalai P, Shousha S. Keratin 19 in paraffin sections of medullary carcinoma and other benign and malignant breast lesions. Mod Pathol. 1995;8:413-416.
16. de Cremoux P, Salomon AV, Liva S, et al. p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst. 1999;91:641-643.
17. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol. 1995;13:821-830.
18. Jensen V, Jensen ML, Kiaer H, Andersen J, Melsen F. MIB-1 expression in breast carcinomas with medullary features: an immunohistological study including correlations with p53 and bcl-2. Virchows Arch. 1997;431:125-130.
19. Querzoli P, Albonico G, Ferretti S, et al. MIB-1 proliferative activity in invasive breast cancer measured by image analysis. J Clin Pathol. 1996;49:926-930.
20. Omoto Y, Inoue S, Ogawa S, et al. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett. 2001;163:207-212.
21. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S. Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma. J Clin Pathol. 1993;46:1009-1010.
22. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features, and prognosis. Cancer. 1995;75:1320-1326.
23. Ro JS, el-Naggar A, Ro JY, et al. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res. 1989;49(24 pt 1):6941-6944.
24. Marx D, Schauer A, Reiche C, et al. c-erbB2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol. 1990;116:15-20.
25. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: a retrospective analysis of 176 cases. Cancer. 1990;65:1794-1800.
26. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319:1239-1245.
27. Bacus SS, Zelnick CR, Chin DM, et al. Medullary carcinoma is associated with expression of intercellular adhesion molecule-1: implication to its morphology and its clinical behavior. Am J Pathol. 1994;145:1337-1348.
28. Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol. 2002;15:116-124.
29. Cook DL, Weaver DL. Comparison of DNA content, S-phase fraction, and survival between medullary and ductal carcinoma of the breast. Am J Clin Pathol. 1995;104:17-22.
30. Kajiwara M, Toyoshima S, Yao T, Tanaka M, Tsuneyoshi M. Apoptosis and cell proliferation in medullary carcinoma of the breast: a comparative study between medullary and non-medullary carcinoma using the TUNEL method and immunohistochemistry. J Surg Oncol Suppl. 1999;70:209-216.
31. Feinmesser M, Sulkes A, Morgenstern S, Sulkes J, Stern S, Okon E. HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities. J Clin Pathol. 2000;53:286-291.
32. Charpin C, Bonnier P, Garcia S, et al. E-cadherin and beta-catenin expression in breast medullary carcinomas. Int J Oncol. 1999;15:285-292.
33. Ugolini F, Charafe-Jauffret E, Bardou VJ, et al. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene. 2001;20:5810-5817.
34. Lee SC, Berg KD, Sherman ME, Griffin CA, Eshleman JR. Microsatellite instability is infrequent in medullary breast cancer. Am. J Clin Pathol. 2001;115:823-827.
35. Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res. 2001;61:7889-7899.
36. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A. 2001;98:12659-12664.
37. Yakirevich E, Izhak OB, Rennert G, Kovacs ZG, Resnick MB. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod Pathol. 1999;12:1050-1056.
38. Gaffey MJ, Frierson HF Jr, Mills SE, et al. Medullary carcinoma of the breast: identification of lymphocyte subpopulations and their significance. Mod PathoL 1993;6:721-728.
39. Lespagnard L, Cochaux P, Larsimont D, Degeyter M, Velu T, Heimann R. Absence of Epstein-Barr virus in medullary carcinoma of the breast as demonstrated by immunophenotyping, in situ hybridization and polymerase chain reaction. Am J Clin Pathol. 1995;103:449-452.
40. Yarden Y. Biology of HER2 and its importance in breast cancer [review] Oncology. 2001;61(suppl 2):1-13.
41. Schnitt SJ. Breast cancer in the 21st century: neu opportunities and neu challenges [review]. Mod PathoL 2001;14:213-218.
42. Naidu R, Yadav M, Nair S, Kutty KK. Immunohistochemical analysis of p53 expression in primary breast carcinomas. Anticancer Res. 1998;18:65-70.
43. Martinazzi M, Crivelli F, Zampatti C, Pisani P. Low, intermediate and high grade breast carcinomas as determined by histotyping, immunohistochemical prognosticators and histological grading. Pathologica. 1992;84:33-47.
44. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.